Next Generation Diabetes Therapy and Drug Delivery Market Report 2025 (Global Edition)

Global Next Generation Diabetes Therapy and Drug Delivery Market Report 2025 Market Size Split by Product (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), by Demog...

Next Generation Diabetes Therapy and Drug Delivery Market Report Description

We have various report editions of Next Generation Diabetes Therapy and Drug Delivery Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Next Generation Diabetes Therapy and Drug Delivery Market Insights Video

Competitive Landscape of the Next Generation Diabetes Therapy and Drug Delivery Market

The market for next-generation diabetes therapy and drug delivery is highly competitive, with major competitors such as Abbott Laboratories, Novo Nordisk, Dexcom, and Medtronic vying for market share. These businesses are committed to innovation, creating cutting-edge products like continuous glucose monitors and intelligent insulin delivery systems. In this quickly changing industry, companies often look to grow their portfolios and solidify their market positions through strategic alliances, mergers, and acquisitions.

In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) announced that the first participant has been successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide (research code: GZR18), a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently developed by Gan & Leem, in Chinese participant with type 2 diabetes mellitus (T2DM). 
https://www.ganlee.com/detail/769.html 
In December 2024, NuGen Medical Devices launched its InsuJet needle-free insulin delivery device in Canada, securing orders for 2,500 units and 750 starter kits, generating $670,000 in revenue, and approved for use in 42 countries, using a spring-loaded mechanism for fast, painless insulin delivery. 
https://www.drugdeliverybusiness.com/nugen-launches-needle-free-insulin-delivery-device-canada/ 
In September 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation Eversense 365 CGM system for individuals aged 18 and older with Type 1 and Type 2 diabetes. Eversense 365 is the world’s first CGM system with a one-year sensor, marking a major advancement in diabetes technology and management. Unlike short-term CGM systems that require sensor changes every 10-14 days, Eversense 365 offers a single insertion and "Day 1" each year, reducing the frequency of sensor replacements. Its 12-month sensor lifespan minimizes the disruptions caused by frequent sensor failures or changes in traditional systems.
https://www.senseonics.com/investor-relations/news-releases/2024/09-17-2024-120118174 
In August 2024, Eli Lilly announced positive topline results from the three-year SURMOUNT-1 study (176-week treatment period), assessing the efficacy and safety of once-weekly tirzepatide (Zepbound and Mounjaro) for long-term weight management and delaying the progression to diabetes in adults with pre-diabetes and obesity or overweight. The weekly injections of tirzepatide (5 mg, 10 mg, 15 mg) reduced the risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight compared to placebo.
https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-risk-developing-type-2-diabetes-94-adults 
In May 2024, Eli Lilly, headquartered in Indianapolis, announced plans to invest an additional USD 5.3 billion in the construction of a large manufacturing facility in Lebanon, Indiana, located 30 miles away. This investment will enhance the production capacity of active pharmaceutical ingredients (APIs) for its injectable tirzepatide products, Mounjaro for type 2 diabetes and Zepbound for obesity.
https://www.fiercepharma.com/manufacturing/eli-lilly-invests-additional-53b-production-diabetes-obesity-drugs-indiana 
 

May 2021: The medical technology company Medtronic plc has been awarded the CE (Conformité Européenne) Mark for its Guardian 4 sensor3. This sensor eliminates the need for fingersticks while calibrating or making treatment decisions for diabetes. Due to the CE Mark, this next-generation sensor can be linked with Medtronic or the MiniMed 780G insulin pump system. (Source:https://news.medtronic.com/2021-05-26-Medtronic-Secures-Two-CE-Mark-Approvals-for-Guardian-4-Sensor-for-InPen-MDI-Smart-Insulin-Pen) September 2020: DexCom, Inc., the leading provider of real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced the creation of the first registry in history dedicated to monitoring the results of CGM use in hospitals during the COVID-19 pandemic by patients and healthcare professionals. (Source:https://investors.dexcom.com/news/news-details/2020/Dexcom-Announces-First-Ever-Registry-Dedicated-to-Tracking-Outcomes-of-In-Hospital-Real-Time-CGM-Use-in-Response-to-the-COVID-19-Pandemic/default.aspx) April 2020: Dexcom announced that the company is temporarily making its Dexcom G6 CGM System available for remote patient monitoring in the hospital setting due to the COVID-19 public health crisis, the need to maintain personal protective equipment, and the desire to decrease the frequency of hospital staff exposure to the coronavirus. (Source:https://www.dexcom.com/news/dexcom-cgm-hospital-covid19)

Top Companies Market Share in Next Generation Diabetes Therapy and Drug Delivery Industry: (In no particular order of Rank)

• Johnson & Johnson
• Abbott Laboratories
• Medtronic
• Sanofi
• Novo Nordisk
• MannKind Corporation
• Enteris BioPharma
• Dexcom
• Senseonics
• Medtech
• Synertech
• Relmada Therapeutics
• Eli Lilly and Company
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Next Generation Diabetes Therapy and Drug Delivery Market

Which Region Dominates the Next Generation Diabetes Therapy and Drug Delivery Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. The market for next-generation diabetes therapy and drug delivery is expected to expand fastest in North America for a number of reasons. Because of the high rate of diabetes in the area, as well as its sophisticated healthcare system and significant R&D expenditures, the adoption of novel treatments is encouraged. The incidence of diabetes, especially type 2 diabetes, is significantly high in North America, fuelled by an ageing population, lifestyles changing, as well as increasing obesity rates. More than 38 million Americans have diabetes, with 90% to 95% of them having type 2 diabetes, most often affecting adults aged 45 and older, but more and more frequently diagnosed in younger people. This increasing diabetes burden makes a high demand for sophisticated management solutions.
https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html 
The presence of major industry players like Abbott Laboratories and Medtronic further accelerates market expansion. The quick adoption of next-generation diabetes treatments is further facilitated by advantageous reimbursement policies and rising diabetes management awareness in the United States and Canada, which positions this region as a major market growth driver.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Next Generation Diabetes Therapy and Drug Delivery market. The industry for next-generation diabetes treatment and drug delivery is expected to expand significantly in the Asia Pacific region due to the region's strengthening healthcare infrastructure and rapidly rising diabetes prevalence. The need for novel therapeutics is being driven by growing healthcare spending in nations like China, India, and Japan, as well as growing knowledge of sophisticated diabetes control choices. Additionally, Asia Pacific is a significant market for next-generation diabetes therapies due to the region's sizable population base and the increasing adoption of digital health technologies. The government's efforts to enhance diabetes care and local manufacturing both contribute to the region's growing market potential.

The current report Scope analyzes Next Generation Diabetes Therapy and Drug Delivery Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Next Generation Diabetes Therapy and Drug Delivery Market Analysis

According to Cognitive Market Research, the global Next Generation Diabetes Therapy and Drug Delivery market size was estimated at USD 10215.6 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 4086.24 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Next Generation Diabetes Therapy and Drug Delivery market with a market size of USD 3224.04 million in 2024 and is projected to grow at a CAGR of 13.2% during the forecast period. This is due to the causes including obesity, sedentary lifestyles, and aging demographics; a sizable portion of the U.S. population has diabetes, especially Type 2.
• The Canada Next Generation Diabetes Therapy and Drug Delivery market had a market share of USD 490.35 million in 2024 and is projected to grow at a CAGR of 14.2% during the forecast period. Because all Canadians have access to basic medical services, including diabetes care, due to the country's universal healthcare system, there is a greater need for novel therapies.
• The Mexico Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 371.85 million in 2024.

Europe Next Generation Diabetes Therapy and Drug Delivery Market Analysis

According to Cognitive Market Research, the global Next Generation Diabetes Therapy and Drug Delivery market size was estimated at USD 10215.6 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 3064.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.7% from 2024 to 2031.

• The United Kingdom's Next Generation Diabetes Therapy and Drug Delivery market had a market share of USD 514.87 million in 2024 and is projected to grow at a CAGR of 14.5% during the forecast period. Diabetes research is being actively pursued by pharmaceutical companies and research organizations in the UK, which is helping to create novel treatment alternatives.
• The France Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 281.95 million in 2024.
• According to Cognitive Market Research, the German Next Generation Diabetes Therapy and Drug Delivery market size was valued at USD 606.81 million in 2024 and is projected to grow at a CAGR of 13.9% during the forecast period. New developments in diabetes treatment options and public awareness have increased in Germany.
• The Italy Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 13.1% during the forecast period, with a market size of USD 263.56 million in 2024.
• The Russian Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 475.03 million in 2024.
• The Spain Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 12.8% during the forecast period with a market size of USD 251.30 million in 2024
• The Luxembourg Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 13.8% during the forecast period, with a market size of USD 95.01 million in 2024.
• The Portugal Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 13.5% during the forecast period, with a market size of USD 64.36 million in 2024.
• The Greece Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 14.0% during the forecast period, with a market size of USD 36.78 million in 2024.
• Rest of Europe's Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 12.4% during the forecast period, with a market size of USD 475.03 million in 2024.

Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Market Analysis

According to Cognitive Market Research, the global Next Generation Diabetes Therapy and Drug Delivery market size was estimated at USD 10215.6 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 2349.59 million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Next Generation Diabetes Therapy and Drug Delivery market size was valued at USD 1057.31 million in 2024 and is projected to grow at a CAGR of 16.7% during the forecast period. The Chinese government is making significant investments to build and upgrade the country's healthcare system, including facilities for the treatment of diabetes.
• The Japan Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 15.7% during the forecast period, with a market size of USD 324.24 million in 2024.
• The India Next Generation Diabetes Therapy and Drug Delivery market had a market share of USD 281.95 million in 2024 and is projected to grow at a CAGR of 19.0% during the forecast period. Advanced diabetes treatment technologies, like insulin pumps and CGM systems, are being adopted and developed in India.
• The South Korean Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 16.3% during the forecast period, with a market size of USD 234.96 million in 2024.
• The Australian Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 16.9% during the forecast period, with a market size of USD 122.18 million in 2024.
• The South East Asia Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 18.2% during the forecast period, with a market size of USD 162.12 million in 2024.
• The Rest of Asia Pacific Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 17.0% during the forecast period, with a market size of USD 166.82 million in 2024.

South America Next Generation Diabetes Therapy and Drug Delivery Market Analysis

According to Cognitive Market Research, the global Next Generation Diabetes Therapy and Drug Delivery market size was estimated at USD 10215.6 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 510.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.6% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Next Generation Diabetes Therapy and Drug Delivery market size was valued at USD 218.61 million in 2024 and is projected to grow at a CAGR of 15.2% during the forecast period. Brazil has experienced a surge in demand for better healthcare services, particularly diabetes treatment, as a result of the country's growing middle class.
• Argentina's Next Generation Diabetes Therapy and Drug Delivery market had a market share of USD 85.81 million in 2024 and is projected to grow at a CAGR of 15.5% during the forecast period. Innovation and competitiveness are encouraged in Argentina by the large number of pharmaceutical businesses operating there both domestically and internationally.
• Colombia's Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 14.4% during the forecast period, with a market size of USD 45.46 million in 2024.
• Peru's Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 14.8% during the forecast period, with a market size of USD 41.88 million in 2024.
• Chile's Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 36.78 million in 2024.
• The Rest of Latin America's Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 82.24 million in 2024.

Middle East Next Generation Diabetes Therapy and Drug Delivery Market Analysis

According to Cognitive Market Research, the global Next Generation Diabetes Therapy and Drug Delivery market size was estimated at USD 10215.6 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 204.31 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.9% from 2024 to 2031..

• The GCC Countries Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 15.7% during the forecast period, with a market size of USD 87.45 million in 2024. GCC countries are collaborating strategically with global pharmaceutical firms to enable access to cutting-edge diabetes treatments and technologies.
• The Egypt Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 15.2% during the forecast period, with a market size of USD 21.45 million in 2024.
• The South African Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 15.9% during the forecast period, with a market size of USD 32.28 million in 2024. The government of South Africa has put laws into place to enhance the payment of diabetic equipment and therapies.
• The Turkey Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 14.4% during the forecast period, with a market size of USD 17.57 million in 2024.
• The Nigeria Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 14.0% during the forecast period, with a market size of USD 21.45 million in 2024.
• The Rest of the MEA Next Generation Diabetes Therapy and Drug Delivery market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 24.11 million in 2024.

Next Generation Diabetes Therapy and Drug Delivery Market Analysis

Next Generation Diabetes Therapy and Drug Delivery Market Product Segment Analysis

According to Cognitive Market Research, CGM systems stand out as the dominant category over the projected period. The industry for next-generation diabetes treatment and drug delivery makes extensive use of continuous glucose monitoring (CGM) systems to measure blood glucose levels in real time. These wearable sensor and transmitter systems continuously check blood sugar levels and communicate data to an insulin pump or mobile device. As a result, there is less need for frequent fingerstick testing, improved glucose control, and more precise insulin dosage adjustments. By offering timely and useful data, CGM devices are especially helpful for treating diabetes and enhancing overall patient outcomes. New models now integrate seamlessly with smartphones and insulin pumps, simplifying glucose level tracking for users. The ability to sync with other digital health tools and wearables further enhances the appeal of CGM systems for both patients and healthcare providers. 
For instance, in July 2024, Roche gained the CE Mark for its Accu-Chek SmartGuide solution for CGM, which will be available for use by adults with type 1 and type 2 diabetes on flexible insulin therapy.
https://www.roche.com/media/releases/med-cor-2024-07-09 
The system transmits real-time glucose values to the Accu-Chek SmartGuide app every five minutes, and the app takes this information and uses it to identify glucose trends and forecast future levels. 

Artificial pancreas emerged as the fastest-growing category in the next-generation diabetes therapy and drug delivery market. Artificial pancreas devices are utilized in the industry for next-generation diabetes treatment and drug delivery to automate glucose monitoring and insulin delivery. These devices use sophisticated algorithms, insulin pumps, and continuous glucose monitoring (CGMs) to control blood sugar levels in real-time. The artificial pancreas replicates the actions of a functional pancreas by autonomously adjusting insulin supply based on glucose measurements. This technology offers a major improvement in individualized diabetes care by assisting in the maintenance of optimal blood glucose levels, lowering the risk of hypo- and hyperglycemia, and improving overall diabetes management.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Next Generation Diabetes Therapy and Drug Delivery Industry. Request a Free Sample PDF!

Next Generation Diabetes Therapy and Drug Delivery Market Demographic Segment Analysis

According to Cognitive Market Research, the dominant category is the adult population. Because type 2 diabetes is more common in adults, the adult population is a key focus of the next-generation diabetes therapy and drug delivery market. Adults constitute a sizable market for advanced diabetes management solutions because of the increased incidence of diabetes due to variables such as obesity, aging, and lifestyle changes. Adults with diabetes and related complications are the target audience for next-generation therapies like artificial pancreas systems and continuous glucose monitoring (CGM) systems, which are intended to enhance quality of life and regulate glycemic levels.

The fastest-growing category in the Next Generation Diabetes Therapy and Drug Delivery market is the child population. The increasing number of children with type 1 diabetes is driving an increased focus on the child population demography in the next-generation diabetes therapy and drug delivery market. Novel treatments, like insulin pumps and continuous glucose monitoring (CGM) devices, are intended to provide accurate glucose control and enhance the quality of life for pediatric patients. These technologies provide specialized solutions to fulfill the specific requirements of pediatric diabetes care, assisting in the management of diabetes with the least amount of disruption to everyday activities and school life.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Next Generation Diabetes Therapy and Drug Delivery Indication Segment Analysis

Next Generation Diabetes Therapy and Drug Delivery Market Indication Segment Analysis

According to Cognitive Market Research, the dominant category is type 2 diabetes. Type 2 diabetes is a leading indicator driving the development of novel treatments in the next-generation diabetes therapy and drug delivery market. Smart insulin pens, continuous glucose monitoring (CGM) devices, and non-invasive drug delivery techniques are examples of cutting-edge treatments for Type 2 diabetes. These technological advancements are intended to facilitate improved disease management, improve patient convenience, and improve blood glucose control. Next-generation medicines address the difficulties of Type 2 diabetes by providing accurate dosing and real-time monitoring. This serves to increase safety and reduce the risk of problems in patient outcomes overall.

The fastest-growing category in the Next Generation Diabetes Therapy and Drug Delivery market is type 1 diabetes. Type 1 diabetes is a key indication driving innovation in the market for next-generation diabetic therapy and drug delivery. Artificial pancreas devices and continuous glucose monitoring (CGM) systems are examples of advanced therapeutics for Type 1 diabetes that provide accurate, real-time glucose control. These technological advancements lessen the need for continuous blood sugar monitoring by automating the supply of insulin. These therapies try to improve glucose control, lower the risk of complications, and improve the general quality of life for people with Type 1 diabetes by closely imitating natural pancreas function.

• Type 1 Diabetes
• Type 2 Diabetes

Next Generation Diabetes Therapy and Drug Delivery End User Segment Analysis

Next Generation Diabetes Therapy and Drug Delivery Market End User Segment Analysis

According to Cognitive Market Research, the dominant category is diagnostic/clinics. Healthcare facilities and diagnostic centers are crucial end users in the next-generation diabetes therapy and drug delivery market. These environments make use of cutting-edge medicines like continuous glucose monitoring (CGM) systems with insulin pumps to manage patients' diabetes accurately. Personalized treatment plans, better patient outcomes, and the implementation and monitoring of these technologies are all made possible by diagnostic clinics. These facilities improve the accuracy of diabetes diagnoses, simplify the management of diabetes, and provide all-encompassing care for patients with Type 1 and Type 2 diabetes by incorporating next-generation diabetic solutions.

The fastest-growing category in the Next Generation Diabetes Therapy and Drug Delivery market is ICUs. Intensive Care Units (ICUs) are significant end users of cutting-edge diabetes management technology in the market for next-generation diabetes therapy and drug delivery. To treat critically ill diabetic patients, intensive care units (ICUs) use automated insulin delivery systems and continuous glucose monitoring (CGM) devices. Precise real-time glucose monitoring and insulin dosage are made possible by these technologies, and they are essential for preserving stable blood glucose levels in intricate medical scenarios. ICUs can improve overall outcomes for critically sick diabetic patients, lessen problems related to glucose imbalances, and improve patient care by implementing next-generation medicines.

• Diagnostic/Clinics
• ICUs
• Home Healthcare

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion